PinPrint
Develops high-resolution 3D-printed microneedle microarray patches (MAPs) for intradermal delivery of vaccines, therapeutics, and aesthetic drugs, as well as interstitial fluid (ISF) sampling.
- CEO / Founder
- Renee Ryan
- Team Size
- 1-10
- Stage
- Early Stage
- Total Funding
- $50K
- Latest Round
- Seed
- Key Investors
- Continuity Biosciences; Hyperspace Ventures
Technology & Products
Key Products
3D-printed microneedle patches for vaccines; 3D-printed microneedle patches for therapeutics; 3D-printed microneedle patches for aesthetic/cosmetic drug delivery; Interstitial fluid (ISF) sampling patches
Technological Advantage
iCLIP technology solves the resin over-curing problem in negative spaces, enabling ultra-precise microchannels and voids unattainable with conventional manufacturing or standard CLIP. This provides a defensible IP moat for producing next-generation microneedle patches with tunable dosing and formulation compatibility, including lyophilized cargos.
Differentiation
Value Proposition
Enables pain-free, precise, and scalable intradermal drug and vaccine delivery, eliminating needles and cold-chain logistics while improving patient compliance and outcomes.
How They Differentiate
Uses proprietary high-resolution 3D printing (iCLIP) to create microneedle patches with integrated microfluidic channels for precise dosing and multi-agent delivery, unlike competitors using traditional molding or laser cutting.
Market & Competition
Target Customers
Pharmaceutical companies, dermatology clinics, healthcare systems, clinical research groups
Industry Verticals
Pharmaceuticals; Medical Devices; Aesthetics; Healthcare
Competitors
Vaxxas; Micron Biomedical; LTS Lohmann Therapie-Systeme AG
Growth & Milestones
Major Milestones
First-in-human study at Stanford (late 2024); Second-in-human study in dermatology for Kaposi Sarcoma patients (2025); Strategic investment from Continuity Biosciences (April 29, 2025); Targeting human study for new product pipeline by September 2025; Planning Series A funding within 12 months of study (circa 2026)